NEWS & EVENTS

Latest news and upcoming events

22 Nov 2021

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Upcoming events
  • Jefferies London Healthcare Conference
    16 November – 18 Nov. 2021,
    London

  • LSX World Congress
    8 February – 9 February 2022,
    London

Dutch med-tech innovator Xeltis lands €15 million European financing from EIB

Xeltis will use the funding to accelerate the clinical programmes of three restorative devices that can substantially impact cardiovascular

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Purchase price includes an upfront payment of EUR 205 million, precommercial milestones for up to EUR 170 million and progressive commercial milestones.

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

Today’s acquisition marks a pivotal moment for Kala and a meaningful acceleration toward our goal of strengthening Kala’s pipeline for the treatment of front and back of the eye diseases,

Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting

AU-011 may offer patients a safe, effective first-line therapy for early-stage disease that preserves vision.

AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access

His responsibilities include ensuring broad patient access to ilofotase alfa, AM-Pharma’s drug candidate for the treatment of sepsis-associated acute kidney injury, currently in Phase III clinical development.

Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ

Aura Biosciences is the sixth portfolio company of Ysios to be listed on NASDAQ, and the third one this year.

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

Upcoming Phase 2 trial marks expansion of Galecto pipeline into oncology and provides opportunity for exploring the use of galectin-3 inhibitors in cancer.

Synendos Therapeutics Appoints Scientific Advisory Board

Scientific Advisory Board made up of prominent scientists with significant CNS expertise

ONA Therapeutics Strengthens Scientific Leadership Team

Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development.

VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001

Funding comprises grant financing of up to €2.5 million and up to €15 million in equity investment

Newsletter

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.